CAMCEVI ETM
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- CAMCEVI ETM
- Generic name
- LEUPROLIDE
- Manufacturer
- Foresee Pharmaceuticals Co., Ltd.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 5fc04a39-4024-4d95-a32c-b8ea6cd6f223
- SPL ID
- 14ea9819-02e5-446c-95c0-1b6133521112
- Version
- 1
- Effective date
- 2025-08-08
- Source export date
- 2026-11-13
- Source partition
- 3
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0003-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/2df682709a18af7b632162dce4573ac151d74d432118e70b8675083d83b89813/drug-label-0003-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 15:47:32
| Harmonized routes |
|---|
| SUBCUTANEOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | NDA | 219745 | derived:openfda.application_number |
| application number | NDA219745 | openfda.application_number | |
| brand name | CAMCEVI ETM | openfda.brand_name | |
| generic name | LEUPROLIDE | openfda.generic_name | |
| manufacturer name | Foresee Pharmaceuticals Co., Ltd. | openfda.manufacturer_name | |
| ndc | package | 72851-100-01 | openfda.package_ndc |
| ndc | product | 72851-100 | openfda.product_ndc |
| ndc11 | package | 72851010001 | derived:openfda.package_ndc |
| rxcui | 2755810 | openfda.rxcui | |
| rxcui | 2755812 | openfda.rxcui | |
| spl id | 14ea9819-02e5-446c-95c0-1b6133521112 | id | |
| spl set id | 5fc04a39-4024-4d95-a32c-b8ea6cd6f223 | set_id | |
| unii | 8E3C3C493W | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS • Tumor Flare: Transient worsening of bone pain, uretral obstruction, spinal cord compression, or the occurrence of additional signs and symptoms of prostate cancer may develop during the first few weeks of treatment. Monitor patients closely and manage symptoms. ( 5.1 ) • Hyperglycemia and Diabetes: Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Monitor blood glucose level and manage according to current clinical practice. ( 5.2 ) • Cardiovascular Diseases: Increased risk of myocardial infarction, sudden cardiac death, and stroke has been reported in men receiving GnRH agonists. Monitor for cardiovascular disease and manage according to current clinical practice. ( 5.3 ) • QT/QTc Prolongation: Androgen deprivation therapy may prolong the QT interval. Consider periodic monitoring of electrocardiograms and electrolytes. ( 5.4 ) • Convulsions: Manage convulsions according to the current clinical practice. ( 5.5 ) • Severe Cutaneous Adverse Reactions: CAMCEVI ETM can cause severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). Interrupt CAMCEVI ETM if signs or symptoms of SCARs develop. Permanently discontinue if SCARs are confirmed. ( 5.6 ) • Embryo-Fetal Toxicity: CAMCEVI ETM may cause fetal harm. ( 5.8 , 8.1 ) 5.1 Tumor Flare CAMCEVI ETM, like other GnRH agonists, causes a transient increase in serum levels of testosterone during the first week of treatment, declining thereafter to baseline levels or below by the end of the second week of treatment. Transient worsening of symptoms, or the occurrence of additional signs and symptoms of prostate cancer, may develop during the first few weeks of CAMCEVI ETM treatment. Patients treated with CAMCEVI ETM may experience a temporary increase in bone pain, which can be managed symptomatically. Cases of ureteral obstruction and spinal cord compression have been observed, which may contribute to paralysis with or without fatal complications. Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy. 5.2 Hyperglycemia and Diabetes Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Hyperglycemia may represent the development of diabetes mellitus or worsening of glycemic control in patients with diabetes. Monitor blood glucose and/or glycosylated hemoglobin (HbA1c) periodically in patients receiving a GnRH agonist and manage with current practice for treatment of hyperglycemia or diabetes. 5.3 Cardiovascular Diseases Increased risk of developing myocardial infarction, sudden cardiac death, and stroke has been reported in association with use of GnRH agonists in men. The risk appears low based on the reported odds ratios and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients receiving a GnRH agonist should be monitored for symptoms and signs suggestive of development of cardiovascular disease and be managed according to current clinical practice. 5.4 QT/QTc Prolongation Androgen deprivation therapy may prolong the QT/QTc interval. Providers should consider whether the benefits of androgen deprivation therapy outweigh the potential risks in patients with congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, and in patients taking drugs known to prolong the QT interval. Electrolyte abnormalities should be corrected. Consider periodic monitoring of electrocardiograms and electrolytes. 5.5 Convulsions Convulsions have been reported in patients receiving GnRH agonists, like CAMCEVI ETM [see Adverse Reactions (6.2) ] . Manage patients receiving a GnRH agonist who experience convulsions according to current clinical practice. 5.6 Severe Cutaneous Adverse Reactions CAMCEVI ETM can cause severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP). SCARs, including SJS/TEN, DRESS, and AGEP, occurred in patients receiving CAMCEVI ETM or other GnRH agonists; including cases with visceral involvement and/or requiring skin grafts [see Adverse Reactions (6.2) ]. Monitor patients for the development of SCARs. If a SCAR is suspected, interrupt CAMCEVI ETM until the etiology of the reaction has been determined. Consultation with a dermatologist is recommended. If a SCAR is confirmed, or for other Grade 4 skin reactions, permanently discontinue CAMCEVI ETM. 5.7 Laboratory Tests Monitor serum levels of testosterone following injection of CAMCEVI ETM. In the majority of patients treated with CAMCEVI ETM, testosterone levels increased above baseline during the first week, and then declined thereafter to castration levels (<50 ng/dL) within 4 weeks [see Clinical Studies (14) and Adverse Reactions (6) ]. 5.8 Embryo-Fetal Toxicity Based on findings in animal studies and mechanism of action, CAMCEVI ETM can cause fetal harm when administered to a pregnant woman. In animal developmental and reproductive toxicology studies, administration of a monthly formulation of leuprolide on day 6 of pregnancy (sustained exposure was expected throughout the period of organogenesis) caused adverse embryo-fetal toxicity in animals at doses less than the human dose based on body surface area using an estimated daily dose. Advise pregnant patients and females of reproductive potential of the potential risk to the fetus [see Use in Specific Population (8.1) , Clinical Pharmacology (12.1) ] .
warnings and cautions
5.1 Tumor Flare CAMCEVI ETM, like other GnRH agonists, causes a transient increase in serum levels of testosterone during the first week of treatment, declining thereafter to baseline levels or below by the end of the second week of treatment. Transient worsening of symptoms, or the occurrence of additional signs and symptoms of prostate cancer, may develop during the first few weeks of CAMCEVI ETM treatment. Patients treated with CAMCEVI ETM may experience a temporary increase in bone pain, which can be managed symptomatically. Cases of ureteral obstruction and spinal cord compression have been observed, which may contribute to paralysis with or without fatal complications. Patients with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed during the first few weeks of therapy.
warnings and cautions
5.2 Hyperglycemia and Diabetes Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Hyperglycemia may represent the development of diabetes mellitus or worsening of glycemic control in patients with diabetes. Monitor blood glucose and/or glycosylated hemoglobin (HbA1c) periodically in patients receiving a GnRH agonist and manage with current practice for treatment of hyperglycemia or diabetes.
warnings and cautions
5.3 Cardiovascular Diseases Increased risk of developing myocardial infarction, sudden cardiac death, and stroke has been reported in association with use of GnRH agonists in men. The risk appears low based on the reported odds ratios and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients receiving a GnRH agonist should be monitored for symptoms and signs suggestive of development of cardiovascular disease and be managed according to current clinical practice.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the labeling: • Tumor Flare [see Warnings and Precautions (5.1)] • Hyperglycemia and Diabetes [see Warnings and Precautions (5.2) ] • Cardiovascular Diseases [see Warnings and Precautions (5.3) ] • QT/QTc Prolongation [see Warnings and Precautions (5.4) ] • Convulsions [see Warnings and Precautions (5.5) ] • Severe Cutaneous Adverse Reactions [See Warnings and Precautions (5.6) ] The most common (≥5%) adverse reactions, including laboratory abnormalities, were increased triglycerides, increased alanine aminotransferase, hot flush, hypertension, decreased hemoglobin, increased sodium, increased aspartate aminotransferase, injection site reaction, weight increase, increased potassium, decreased neutrophils, and decreased white blood cells. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Foresee Pharmaceuticals at 1-866-941-7875 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of CAMCEVI ETM was evaluated in an open-label, single arm, clinical trial (FP01C-17-001), patients with advanced prostate cancer received CAMCEVI ETM administered subcutaneously at a dose of 21 mg on Day 0 and Day 84 [see Clinical Studies (14) ]. Of 144 patients enrolled, 132 (92%) received both doses of CAMCEVI ETM. Serious adverse reactions occurred in 6% of patients who received CAMCEVI ETM. Serious adverse reactions included acute myocardial infarction, cerebrovascular accident, drug induced liver injury, and pancreatitis (each 0.7%). Permanent discontinuation of CAMCEVI ETM due to an adverse reaction occurred in 0.7% of patients (stroke). The most common (≥5%) adverse reactions, including laboratory abnormalities, were increased triglycerides, increased alanine aminotransferase, hot flush, hypertension, decreased hemoglobin, increased sodium, increased aspartate aminotransferase, injection site reaction, weight increase, increased potassium, decreased neutrophils, and decreased white blood cells. Table 1 summarizes the most common (≥5%) adverse reactions in FP01C-17-001. Table 1. Adverse Reactions Occurring in ≥5% of Patients - FP01C-17-001 a Only includes a grade 3 adverse reaction. Hypertension includes blood pressure increased, essential hypertension, and hypertension. b Injection site reaction includes injection site erythema, hemorrhage, induration, nodule, localized edema; and injection site pain. Adverse Reaction All Grades N = 144 (%) Grade 3-4 a N = 144 (%) Hot flush 24 0 Hypertension a 15 0.7 Injection site reaction b 10 0 Weight increase 8 0 Clinically relevant adverse reactions in < 5% of patients who received CAMCEVI ETM included insomnia, acute myocardial infarction, cerebrovascular accident, diabetes mellitus, decreased libido, and electrocardiogram QT prolonged. Table 2 summarizes laboratory abnormalities in FP01C-17-001. Table 2. Laboratory Abnormalities Occurring in ≥5% of Patients - FP01C-17-001 a Only includes a grade 3 adverse reaction. Laboratory Abnormality All Grades N = 144 (%) Grade 3-4 a N = 144 (%) Chemistry Increased triglycerides 44 1.4 Increased alanine aminotransferase 28 0.7 Increased sodium 13 0 Increased aspartate aminotransferase 13 0 Increased potassium 7 0 Hematology Decreased hemoglobin 15 0 Decreased neutrophils 6 0 Decreased white blood cells 6 0 6.2 Postmarketing Experience The following adverse reactions have been identified during post approval use of leuprolide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. During postmarketing surveillance, which includes other dosage forms and other patient populations, the following adverse reactions were reported. Allergic Conditions: anaphylactoid or asthmatic process, rash, urticaria, and photosensitivity reactions Cardiovascular System: hypotension, myocardial infarction, pulmonary embolism Central/Peripheral Nervous System: convulsion, peripheral neuropathy, spinal fracture/paralysis Endocrine System: pituitary apoplexy, diabetes Hepato-biliary disorder: drug-induced liver injury Hematologic: white blood cells decreased Psychiatric: mood swings, including depression, suicidal ideation and attempt Respiratory, thoracic and mediastinal disorder: interstitial lung disease Musculoskeletal System: decreased bone density, tenosynovitis-like symptoms, fibromyalgia Skin and Subcutaneous: injection site reactions, SJS/TEN, DRESS, AGEP, dermatitis exfoliative, bullous dermatitis, and erythema multiforme Urogenital System: prostate pain
adverse reactions table
<table ID="_Ref208475159" width="100%"> <caption>Table 1. Adverse Reactions Occurring in ≥5% of Patients - FP01C-17-001</caption> <col width="33%"/> <col width="33%"/> <col width="33%"/> <tfoot> <tr> <td align="left" colspan="3" valign="top"> <sup>a</sup> Only includes a grade 3 adverse reaction. Hypertension includes blood pressure increased, essential hypertension, and hypertension. <sup>b</sup> Injection site reaction includes injection site erythema, hemorrhage, induration, nodule, localized edema; and injection site pain.</td> </tr> </tfoot> <tbody> <tr> <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph> <content styleCode="bold">Adverse Reaction</content> </paragraph> </td> <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph> <content styleCode="bold">All Grades </content> </paragraph> <paragraph> <content styleCode="bold">N = 144</content> </paragraph> <paragraph> <content styleCode="bold">(%)</content> </paragraph> </td> <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph> <content styleCode="bold">Grade 3-4<sup>a</sup> </content> <content styleCode="bold">N = 144</content> <content styleCode="bold">(%)</content> </paragraph> </td> </tr> <tr> <td styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>Hot flush</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>24</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>Hypertension<sup>a</sup> </paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>15</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>0.7</paragraph> </td> </tr> <tr> <td styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>Injection site reaction<sup>b</sup> </paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>10</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph>Weight increase</paragraph> </td> <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph>8</paragraph> </td> <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph>0</paragraph> </td> </tr> </tbody> </table>
adverse reactions table
<table ID="_Ref208475206" width="100%"> <caption>Table 2. Laboratory Abnormalities Occurring in ≥5% of Patients - FP01C-17-001 </caption> <col width="33%"/> <col width="33%"/> <col width="33%"/> <tfoot> <tr> <td align="left" colspan="3" valign="top"> <sup>a</sup> Only includes a grade 3 adverse reaction.</td> </tr> </tfoot> <tbody> <tr> <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph> <content styleCode="bold">Laboratory Abnormality</content> </paragraph> </td> <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph> <content styleCode="bold">All Grades</content> <content styleCode="bold">N = 144</content> <content styleCode="bold">(%)</content> </paragraph> </td> <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph> <content styleCode="bold">Grade 3-4<sup> a</sup> </content> <content styleCode="bold">N = 144</content> <content styleCode="bold">(%)</content> </paragraph> </td> </tr> <tr> <td colspan="3" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph> <content styleCode="bold">Chemistry</content> </paragraph> </td> </tr> <tr> <td styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>Increased triglycerides</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>44</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>1.4</paragraph> </td> </tr> <tr> <td styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>Increased alanine aminotransferase</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>28</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>0.7</paragraph> </td> </tr> <tr> <td styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>Increased sodium</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>13</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>Increased aspartate aminotransferase</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>13</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>Increased potassium</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>7</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>0</paragraph> </td> </tr> <tr> <td colspan="3" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph> <content styleCode="bold">Hematology</content> </paragraph> </td> </tr> <tr> <td styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>Decreased hemoglobin</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>15</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>Decreased neutrophils</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>6</paragraph> </td> <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="top"> <paragraph>0</paragraph> </td> </tr> <tr> <td styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph>Decreased white blood cells</paragraph> </td> <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph>6</paragraph> </td> <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="top"> <paragraph>0</paragraph> </td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.